# US 11,111,217 B2 · 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,217 B2
- Document ID: US11111217B2
- Status: Granted
- Kind: B2
- Application number: 17/068,985
- Filed: 2020-10-13
- Published: 2021-03-04
- Granted: 2021-09-07
- Earliest claimed: 2018-08-06
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Samuel D. Banister; Edgar Engleman; Khoa D. Nguyen; Mark Smith
- Web page: https://patentgrep.com/patent/US11111217B2

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C07D 235/08: Radicals containing only hydrogen and carbon atoms
- C07D 235/18: with aryl radicals directly attached in position 2
- C07D 263/57: Aryl or substituted aryl radicals
- C07D 277/66: with aromatic rings or ring systems directly attached in position 2
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07F 9/65068: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The compound 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-5-ol: and its use are disclosed. The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.

## Claims

### Claim 1

A pharmaceutical composition comprising a compound of formula:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier wherein the pharmaceutical composition is suitable for oral or parenteral administration.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the carrier is suitable for oral administration.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the carrier is suitable for parenteral administration.